This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Designed by active researchers, this workshop focuses on a broad spectrum [….]
Flow Cytometry: Principles, Methods and Applications

This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Designed by active researchers, this workshop focuses on a broad spectrum [….]
NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced the first Clinical Trial Application (CTA) authorization in the European Union (EU). This authorization comes from Italy’s Agenzia Italiana Del Farmaco (AIFA) for the company’s ongoing Phase 2 study of NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in combination with Bristol-Myers Squibb Company’s (NYSE: BMY) Opdivo® (nivolumab), a PD-1 blocking antibody, versus nivolumab monotherapy.
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in progressive multifocal leukoencephalopathy (PML), a rare but very aggressive, opportunistic brain infection. PML is caused by the reactivation of John Cunningham virus (JCV) in immunocompromised individuals, and there are currently no approved therapies for this illness. This investigator-initiated study is being led by Irene Cortese, M.D., of the National Institute of Neurological Disorders and Stroke (NINDS)/National Institute of Health (NIH).
Rockville’s NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), [….]
NeoImmuneTech Announces Closing of Initial Public Offering ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 [….]
Philadelphia-based CARISMA Therapeutics Inc. secured $47 million in a Series B financing round that will be used to advance the development of the company’s novel chimeric antigen receptor macrophages (CAR-M) immunotherapies.
Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.